PWM
RPRX icon

Perigon Wealth Management’s Royalty Pharma RPRX Stock Holding History

Perigon Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
5,996
+206
+4% +$10.7K 0.01% 1053
2026
Q1 		$278K Buy
+5,790
New +$254K 0.01% 1049
2024
Q4 		– Sell
-21,562
Closed -$610K – 1087
2024
Q3 		$610K Buy
+21,562
New +$597K 0.02% 558

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perigon Wealth Management's RPRX Position: Q2 2026 in Review

Perigon Wealth Management increased its Royalty Pharma (RPRX) stake by 3.6% in Q2 2026, buying an estimated $10.7K and bringing the position to 5,996 shares worth $336K. The position accounts for 0.01% of the portfolio, ranked #1053.

Perigon Wealth Management first reported a position in RPRX in Q3 2024 and has held it in 3 quarters since. The position peaked at $610K in Q3 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Perigon Wealth Management held 5,996 shares of Royalty Pharma worth $336K as of Q2 2026.
  • Perigon Wealth Management bought 206 Royalty Pharma shares in Q2 2026, an estimated $10.7K.
  • Royalty Pharma made up 0.01% of Perigon Wealth Management's portfolio in Q2 2026, its #1053 holding.
  • Perigon Wealth Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 3 quarters since.
  • Perigon Wealth Management's Royalty Pharma position peaked at $610K in Q3 2024.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.